EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib

Shubin W Shahab, Matthew Schniederjan, Jose Velazquez Vega, Stephen Little, Andrew Reisner, Tobey MacDonald, Dolly Aguilera

Frontiers in Oncology · 24.02.2023 · 13

DOI: 10.3389/fonc.2023.1123378 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 24.02.2023. Verfasst von Shubin W Shahab und 6 weiteren Autor:innen. Beteiligte Einrichtung: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CURE Childhood Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Infant type hemispheric gliomas are a rare tumor with unique molecular characteristics. In many cases these harbor mutations in receptor tyrosine kinase pathways and respond to targeted therapy. Here we describe the case of an infant with this type of tumor with a novel ATIC-ALK fusion that has responded dramatically to the ALK inhibitor lorlatinib, despite being refractory to standard chemotherapy. Case description The infant was initially treated with standard chemotherapy and found to have an ATIC-ALK fusion. When surveillance imaging revealed progressive disease, the patient was switched to the ALK-inhibitor lorlatinib at 47 mg/m 2 /day. The patient demonstrated a significant clinical and radiographic response to the ALK inhibitor lorlatinib after just 3 months of treatment and a near complete response by 6 months of therapy.

Conclusion

The ALK inhibitor lorlatinib is an effective targeted therapy in infant type hemispheric glioma patients harboring ATIC-ALK fusion.

Schlagwörter

Stichwörter der Autor:innen

ALK fusioncase reporthigh grade gliomainfant-type hemispheric gliomalorlatinib

Autor:innen und Institutionen

  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, United States.
  • Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.
  • Department of Pathology, Emory University School of Medicine, Atlanta, GA, United States.
  • Children's Healthcare of Atlanta, Atlanta, GA, United States.
  • Department of Radiology, Emory University School of Medicine, Atlanta, GA, United States.
  • Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, United States.

Förderung

  • CURE Childhood Cancer

Zitieren

APA

Shahab, S. W., Schniederjan, M., Vega, J. V., Little, S., Reisner, A., MacDonald, T., & Aguilera, D. (2023). Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1123378

Vancouver

Shahab SW, Schniederjan M, Vega JV, Little S, Reisner A, MacDonald T, et al. Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1123378

BibTeX
@article{Shahab2023,
  author = {Shahab, Shubin W and Schniederjan, Matthew and Vega, Jose Velazquez and Little, Stephen and Reisner, Andrew and MacDonald, Tobey and Aguilera, Dolly},
  title = {Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1123378}
}
Kostenlos starten →